Olympus Corporation (TYO:7733)
Japan · Delayed Price · Currency is JPY 1,815.00
-16.50 (-0.90%)
Sep 10, 2025, 3:30 PM JST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
Scientific Solutions Division | - | Log In | Log In | Log In | Log In | Upgrade |
Scientific Solutions Division Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Division Revenue (Pre-FY2025 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Other Division Revenue (Pre-FY2025 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 530.00M | Log In | Log In | Log In | Log In | Upgrade |
Endoscopic Solutions Division | 636.14B | Log In | Log In | Log In | Log In | Upgrade |
Endoscopic Solutions Division Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Therapeutic Solutions Division | 360.66B | Log In | Log In | Log In | Log In | Upgrade |
Therapeutic Solutions Division Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Division Revenue (Post-FY2024 Reporting) | 530.00M | Log In | Log In | Log In | Log In | Upgrade |
Gastrointestinal Solutions Division | 674.04B | Log In | Log In | Log In | Log In | Upgrade |
Surgical & Interventional Solutions Division | 322.76B | Log In | Log In | Log In | Log In | Upgrade |
Other | 530.00M | Log In | Log In | Log In | Log In | Upgrade |
Other | 530.00M | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
Other | -15.16B | Log In | Log In | Log In | Log In | Upgrade |
Scientific Solutions Division Operating Profit | - | Log In | Log In | Log In | Log In | Upgrade |
Scientific Solutions Division Operating Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Division Operating Profit (Pre-FY2025 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Other Division Operating Profit (Pre-FY2025 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Eliminations from Division Operating Profit | -39.92B | Log In | Log In | Log In | Log In | Upgrade |
Eliminations from Division Operating Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | -15.16B | Log In | Log In | Log In | Log In | Upgrade |
Endoscopic Solutions Division Operating Profit | 141.40B | Log In | Log In | Log In | Log In | Upgrade |
Endoscopic Solutions Division Operating Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Therapeutic Solutions Division Operating Profit | 61.45B | Log In | Log In | Log In | Log In | Upgrade |
Therapeutic Solutions Division Operating Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Division Operating Profit (Post-FY2024 Reporting) | -473.00M | Log In | Log In | Log In | Log In | Upgrade |
Gastrointestinal Solutions Division Operating Profit | 168.37B | Log In | Log In | Log In | Log In | Upgrade |
Surgical & Interventional Solutions Division Operating Profit | 14.21B | Log In | Log In | Log In | Log In | Upgrade |
Other | -15.16B | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
Other | 530.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -94.40% | Log In | Log In | Log In | Log In | Upgrade |
Other | 530.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -94.40% | Log In | Log In | Log In | Log In | Upgrade |
Japan | 110.11B | Log In | Log In | Log In | Log In | Upgrade |
Japan Growth | -6.21% | Log In | Log In | Log In | Log In | Upgrade |
North America | 413.81B | Log In | Log In | Log In | Log In | Upgrade |
North America Growth | 5.13% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 254.62B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | 2.13% | Log In | Log In | Log In | Log In | Upgrade |
Other Countries | 28.84B | Log In | Log In | Log In | Log In | Upgrade |
Other Countries Growth | 8.54% | Log In | Log In | Log In | Log In | Upgrade |
China | 95.72B | Log In | Log In | Log In | Log In | Upgrade |
China Growth | -12.95% | Log In | Log In | Log In | Log In | Upgrade |
Asia and Oceania Revenue (Post-FY2019 Reporting) | 93.69B | Log In | Log In | Log In | Log In | Upgrade |
Asia and Oceania Revenue (Post-FY2019 Reporting) Growth | 7.80% | Log In | Log In | Log In | Log In | Upgrade |
Other | 530.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -94.40% | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
Company's Total Revenue Growth Rate After FX Adjustment | - | Log In | Log In | Log In | Log In | Upgrade |
Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment | 4.00% | Log In | Log In | Log In | Log In | Upgrade |
Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment | 3.00% | Log In | Log In | Log In | Log In | Upgrade |
ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment | 3.00% | Log In | Log In | Log In | Log In | Upgrade |
ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment | 5.00% | Log In | Log In | Log In | Log In | Upgrade |
ESD - Medical Service Revenue Growth Rate After FX Adjustment | 5.00% | Log In | Log In | Log In | Log In | Upgrade |
TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment | 2.00% | Log In | Log In | Log In | Log In | Upgrade |
TSD - Urology Revenue Growth Rate After FX Adjustment | 6.00% | Log In | Log In | Log In | Log In | Upgrade |
TSD - Respiratory Revenue Growth Rate After FX Adjustment | 10.00% | Log In | Log In | Log In | Log In | Upgrade |
TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment | -7.00% | Log In | Log In | Log In | Log In | Upgrade |